Navigation Links
Second Phase III Study Evaluating Gilead's Viread for the Treatment,of Chronic Hepatitis B Virus Meets Primary Endpoint

FOSTER CITY, Calif.--(BUSINESS WIRE)--Jun 25, 2007 - Gilead Sciences, Inc. (Nasdaq:GILD) today announced that Study 103, a Phase III clinical trial evaluating the company's once-daily anti-HIV drug Viread(R) (tenofovir disoproxil fumarate or tenofovir DF) 300 mg as a potential treatment for chronic hepatitis B virus (HBV) infection, met its primary efficacy endpoint. The data show that Viread is non-inferior to the company's once-daily antiviral drug Hepsera(R) (adefovir dipivoxil) among patients with "e" antigen (HBeAg)-positive chronic hepatitis B. The primary efficacy endpoint, the proportion of patients with a complete response at week 48, was defined by serum HBV DNA levels below 400 copies/mL and histologic improvement characterized by at least a two point reduction in the Knodell necroinflammatory score (a measure of necro-inflammation - an inflammatory process in the liver including or leading to death of liver cells) with no concurrent worsening of fibrosis (scarring of liver tissue).

At 48 weeks, 66.5 percent of patients in the Viread arm (n=176) had a complete response compared to 12.2 percent in the Hepsera arm (n=90; p less than 0.001). The most commonly observed treatment-emergent adverse events of moderate intensity or higher were abdominal pain, back pain, headache, respiratory infections and transaminase elevations. The incidence of these events was comparable between the Viread and Hepsera arms of the study. In addition, the most frequently observed grade 3 or 4 laboratory abnormalities were elevations in transaminase and serum amylase and were comparable between the two arms. Full study results will be submitted for presentation at an upcoming scientific meeting.

Study 103 is the second of two Phase III pivotal studies evaluating the efficacy, safety and tolerability of Viread for the treatment of chronic hepatitis B to have met its primary efficacy endpoint. Earlier this month, the co
'"/>




Page: 1 2 3 4 5 6

Related medicine technology :

1. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
2. Second Phase III Study Evaluating Gileads Viread for the Treatment of Chronic Hepatitis B Virus Meets Primary Endpoint
3. Second Successful Quigley QR-443 Study Suggests Method of Action Relevant to Broad Range of Chronic Inflammatory Diseases - Human Study to Follow -
4. NeurogesX Announces Presentation of Positive Phase 3 Clinical Data at the Second International Congress on Neuropathic Pain Meeting (NeuPSIG)
5. Repros Androxal Shows Highly Statistically Significant Positive Effects in Men with Secondary Hypogonadism
6. Pharmions Amrubicin Shows Encouraging Results Compared to Standard of Care in Second Line Treatment of Small Cell Lung Cancer
7. Positive Results for Second-Generation Taxus Liberte Coronary Stent System Highlighted in Journal of American College of Cardiology
8. Kosan Presents Promising Phase 1 Data on Second-Generation Hsp90 Inhibitor, Alvespimycin, Showing Antitumor Activity in Refractory Breast and Ovarian Cancers at ASCO
9. Gilead Announces Achievement of Primary Efficacy Endpoint in Second Phase III Study of Aztreonam Lysine for Inhalation in Patients With Cystic Fibrosis
10. Amlodipine and Olmesartan Study Results Released;Late Breaker Presented at American Society of Hypertension Twenty-Second Annual Scientific Meeting (ASH 2007)
11. Amlodipine and Olmesartan Study Results Released; Late Breaker Presented at American Society of Hypertension Twenty-Second Annual Scientific Meeting (ASH 2007)
Post Your Comments:
(Date:1/23/2015)... ( http://www.researchandmarkets.com/research/vzhr6h/video ) has announced the addition of ... Growth, Trends and Forecast 2014 - 2020" report to ... of fascination since the era of the cold war between ... Russia. Earlier even a small glimpse of human form was ...
(Date:1/23/2015)... analysis of Centers for Medicare and Medicaid Services, (CMS) ... percent of seniors chose lower-cost preferred pharmacy plans that ... The findings were released by Drug Channels . ... of Medicare Part D," said Pharmaceutical Care Management Association ...
(Date:1/23/2015)... DUBLIN , Jan. 23, 2015  Immune Therapeutics, Inc. ... Biotechnology, Inc. for the compounding, packaging and distributing of its ... the United States . ... of compounding naltrexone tablets in various strengths for individual patients ...
Breaking Medicine Technology:Video Telemedicine Market- Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2014 - 2020 2Video Telemedicine Market- Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2014 - 2020 3New Analysis: 81 Percent of Medicare Part D Seniors Choose "Preferred Pharmacy" Plans in 2015 2Immune Therapeutics, Inc. Announces Agreement with KRS Global Biotechnology, Inc. 2Immune Therapeutics, Inc. Announces Agreement with KRS Global Biotechnology, Inc. 3Immune Therapeutics, Inc. Announces Agreement with KRS Global Biotechnology, Inc. 4
... 2012  The use of an injectable, clot-preventing drug known ... advanced cancer complicated by blood clots increased steadily between ... in The Oncologist , funded by the National ... despite previous research indicating LMWH is the preferred first-line ...
... 2012  MolecularHealth, Inc., a leader in clinico-molecular informatics™, ... collaboration agreement with the U.S. Food and Drug ... Molecular Analysis of Side Effects (MASE), a ... assessment and prediction. The FDA,s Center ...
Cached Medicine Technology:Injectable Treatment for Blood Clots in Advanced Cancer Patients Increases, According to New Research 2Injectable Treatment for Blood Clots in Advanced Cancer Patients Increases, According to New Research 3MolecularHealth and FDA to Collaborate on Analytical Tools for Mechanism-Based Drug Safety Assessment 2
(Date:1/22/2015)... (PRWEB) January 22, 2015 Juvent Sports ... at the 2015 PGA Merchandise Show to bestow a ... incredible female amateur golfer, Arlene McKitrick. The award commemorated ... amateur golf tournament win. She won her first amateur ...
(Date:1/22/2015)... 22, 2015 Thousand of GranuFlo lawsuits ... recalled its GranuFlo and NaturaLyte dialysis concentrates continue to ... U.S. District Court, District of Massachusetts, Bernstein Liebhard LLP ... Court has remanded a case filed by the state ...
(Date:1/22/2015)... January 22, 2015 For over 20 years, Dr. ... Oceanside and Vista area has treated just about every type ... injury circumstances. And for those same twenty-plus years, the team ... all those injuries with the best possible doctor. With ...
(Date:1/22/2015)... Plainsboro, NJ (PRWEB) January 22, 2015 ... advocate and keynote speaker at the upcoming 32nd ... by ACCME-accredited Physicians’ Education Resource®, LLC (PER®) , ... breast would have gone undetected if she had not ...
(Date:1/22/2015)... Calif. (PRWEB) January 22, 2015 ... Susan Bonilla (D-Concord) and Kristin Olsen (R-Modesto) were ... their leadership in advancing biotechnology, biomedical science, medical ... and Olsen each received the “2014 Life Sciences ...
Breaking Medicine News(10 mins):Health News:All-Time Leading Female Amateur Golfer Arlene McKitrick Receives Juvent Sports Achievement Award at 2015 PGA Show 2Health News:All-Time Leading Female Amateur Golfer Arlene McKitrick Receives Juvent Sports Achievement Award at 2015 PGA Show 3Health News:Court Overseeing Federal GranuFlo Lawsuits Remands Louisiana Claim Back to State Court, Bernstein Liebhard LLP Reports 2Health News:Court Overseeing Federal GranuFlo Lawsuits Remands Louisiana Claim Back to State Court, Bernstein Liebhard LLP Reports 3Health News:Court Overseeing Federal GranuFlo Lawsuits Remands Louisiana Claim Back to State Court, Bernstein Liebhard LLP Reports 4Health News:Industry Leading Chiropractor in Oceanside Joins the Doctors on Liens Network 2Health News:Joan Lunden Reveals Diagnostic Approach That Led To Early Detection;To Keynote 32nd Annual Miami Breast Cancer Conference® 2Health News:Joan Lunden Reveals Diagnostic Approach That Led To Early Detection;To Keynote 32nd Annual Miami Breast Cancer Conference® 3Health News:Joan Lunden Reveals Diagnostic Approach That Led To Early Detection;To Keynote 32nd Annual Miami Breast Cancer Conference® 4Health News:Joan Lunden Reveals Diagnostic Approach That Led To Early Detection;To Keynote 32nd Annual Miami Breast Cancer Conference® 5Health News:Joan Lunden Reveals Diagnostic Approach That Led To Early Detection;To Keynote 32nd Annual Miami Breast Cancer Conference® 6Health News:California Biomedical Community Honors Senator Holly Mitchell, Assemblymembers Susan Bonilla & Kristin Olsen 2Health News:California Biomedical Community Honors Senator Holly Mitchell, Assemblymembers Susan Bonilla & Kristin Olsen 3
... MSY), the,global application software and services company, today announces ... Misys Risk Vision,following a successful project to extend the ... employees at Commerzbank now use the enhanced risk management,solution ... global exposure to,credit risk across the entire business., ...
... down the long stretch of a race track, two different ... to preventing stroke among people with clogged neck arteries and ... a minimally-invasive procedure were just as likely to suffer a ... had open-neck surgery. , The findings should help guide the ...
... with Tully,s Coffee benefits Children,s Hospital, SEATTLE, ... weekly winners of its "Super-Long Coffee Order" promotion ... to nominate their preferred,"super-long" coffee orders and benefits ... $1 for each entry., The winners from ...
... LOS ANGELES, April 9 The Los ... of children hospitalized for,cancer and other serious ... Place, a half block from its original ... provide low cost, often free, lodging to,75-families ...
... found it shaved 10 to 12 years off biological age ... maintains aerobic fitness may delay biological aging by up to ... types of aerobic exercise improve the body,s oxygen consumption and ... in maximal aerobic power begins in middle age, decreasing about ...
... at Tri-City Medical Center (TCMC) achieved union recognition,Wednesday ... Service,confirmed that caregivers strongly supported unionization and had ... TCMC caregivers become members of SEIU United Healthcare ... workers who have achieved industry a,voice on the ...
Cached Medicine News:Health News:Commerzbank Goes Live With Misys Risk Vision 5.4, Following a Successful, On Schedule Implementation Project 2Health News:It's neck-and-neck down the long stretch for 2 stroke-prevention procedures 2Health News:It's neck-and-neck down the long stretch for 2 stroke-prevention procedures 3Health News:It's neck-and-neck down the long stretch for 2 stroke-prevention procedures 4Health News:PEMCO's Super-Long-Coffee-Order Contest Taps First Winners 2Health News:Los Angeles Ronald McDonald House Doubles Lodging Capacity for Families of Hospitalized Children 2Health News:Los Angeles Ronald McDonald House Doubles Lodging Capacity for Families of Hospitalized Children 3Health News:Aerobic Exercise Keeps You Young 2Health News:North County Caregivers Join United Healthcare Workers 2
ThermalSeal RT (2mil) is Optically Clear for Real Time PCR and easy to apply. Works for all plates....
DMSO-resistant microplate sealing film...
Sealing tape, white Rayon, breathable, NS...
Sealing tape, slightly stiffer than Polyolefin tape. Certified RNase and DNase free....
Medicine Products: